SOST and postmenopausal osteoporosis: Some anti-sclerostin antibodies, such as romosozumab and blosozumab, are being tested in clinical trials for the treatment of postmenopausal osteoporosis via neutralizing SOST, and the relevant trial outcomes are promising [36].